Cell surface receptor for the cytokine IL10 that participates in IL10-mediated anti-inflammatory functions, limiting excessive tissue disruption caused by inflammation. Upon binding to IL10, induces a conformational change in IL10RB, allowing IL10RB to bind IL10 as well (PubMed:16982608). In turn, the heterotetrameric assembly complex, composed of two subunits of IL10RA and IL10RB, activates the kinases JAK1 and TYK2 that are constitutively associated with IL10RA and IL10RB respectively (PubMed:12133952). These kinases then phosphorylate specific tyrosine residues in the intracellular domain in IL10RA leading to the recruitment and subsequent phosphorylation of STAT3. Once phosphorylated, STAT3 homodimerizes, translocates to the nucleus and activates the expression of anti-inflammatory genes. In addition, IL10RA-mediated activation of STAT3 inhibits starvation-induced autophagy (PubMed:26962683). Interacts with IL10 (PubMed:16982608, PubMed:15837194). Interacts with IL10RB (PubMed:16982608). Interacts (via its cytoplasmic domain) with JAK1 (via N-terminus) (PubMed:12133952). Interacts with BTRC; this interaction leads to IL10RA ubiquitination and subsequent degradation (PubMed:22087322). Interacts with STAT3 (By similarity). (Microbial infection) Interacts with human cytomegalovirus protein IL10. (Microbial infection) Interacts with Epstein-Barr virus protein IL10. Primarily expressed in hematopoetic cells including B-cells, T-cells, NK cells, monocytes and macrophages. Not expressed in non-hematopoetic cells such as fibroblasts or endothelial cells. Phosphorylated. Phosphorylation of the cytoplasmic tail induced STAT3 activation. Ubiquitinated by BTRC; ubiquitination leads to endocytosis and subsequent degradation of IL10RA. The disease is caused by variants affecting the gene represented in this entry. Belongs to the type II cytokine receptor family.